Post-Case Assessment Questions
1 / 5
1. What are the currently-funded treatment options in Canada for patients with MM relapsing after first-line treatment with DRd? (select all that apply)
2 / 5
2. Which factors impact your recommendation for this patient’s second-line treatment? (select one)
3 / 5
3. Which patient and/or disease characteristics have been associated with improved PFS in response to treatment with XVd in the BOSTON study? (select all that apply)
4 / 5
4. What considerations would you make to determine the starting dose of selinexor? (select all that apply)
5 / 5
5. How can the potential gastrointestinal AEs related to selinexor best be mitigated?
Your score is
Restart quiz
Forus Therapeutics and Catalytic Health – ©2024 – All Rights Reserved